UCB SA (OTCMKTS:UCBJF – Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $321.05, but opened at $294.00. UCB shares last traded at $310.14, with a volume of 8 shares traded.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on UCBJF. Wolfe Research assumed coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating for the company. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, UCB has an average rating of “Buy”.
Check Out Our Latest Report on UCB
UCB Stock Performance
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
See Also
- Five stocks we like better than UCB
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
